AMPK–SQSTM1 Feedback Loop Under Metabolic Stress

Metabolic stress is not simply a consequence of tumor growth; it is also a selective pressure that shapes cancer-cell survival. Glucose limitation, impaired mitochondrial respiration, nutrient depletion, and reactive oxygen species (ROS) accumulation can reinforce one another, threatening ATP production and redox balance. The reference study, Metabolic stress induces a double-positive feedback loop between AMPK and SQSTM1/p62 conferring dual activation of AMPK and NFE2L2/NRF2 to synergize antioxidant defense, addresses how tumor cells coordinate two major stress-adaptation systems under these conditions.

Study Background and Research Question

STK11/LKB1 activates AMP-activated protein kinase (AMPK) when cellular energy status declines. AMPK helps restore energetic balance by limiting ATP-consuming processes and supporting pathways that preserve ATP and NADPH. In parallel, the KEAP1–NFE2L2/NRF2 axis induces antioxidant and cytoprotective programs. These pathways are especially relevant in non-small cell lung cancer (NSCLC), where STK11/LKB1 and KEAP1 alterations can occur together.

The biological problem is that loss of STK11 weakens canonical AMPK signaling, whereas loss of KEAP1 can increase NRF2 activity. The study asked whether these pathways are functionally independent or whether metabolic stress reveals regulatory crosstalk between them. More specifically, the authors examined whether SQSTM1/p62, a stress-responsive autophagy adaptor, could coordinate AMPK and NRF2 activation and whether AMPK in turn regulates SQSTM1.

Key Innovation from the Reference Study

The central innovation is the identification of a double-positive feedback loop between AMPK and SQSTM1/p62. Under metabolic stress, SQSTM1 is not only an autophagy-associated scaffold or substrate receptor. Its increased expression and phosphorylation help activate both branches of the stress response: NRF2 through autophagic degradation of KEAP1, and AMPK through formation of an AXIN–STK11–AMPK signaling complex at the lysosomal membrane.

The reciprocal arm of the loop is equally important. STK11–AMPK activity is required for the stress-induced increase in SQSTM1 expression and phosphorylation. The proposed model therefore differs from a simple linear pathway in which AMPK acts upstream of antioxidant defense. Instead, SQSTM1 and AMPK amplify one another, allowing a metabolic challenge to produce coordinated energetic and antioxidant adaptation. The authors argue that this circuitry may help explain why STK11 and KEAP1 alterations can be selected together in tumors facing nutrient and oxidative stress.

Methods and Experimental Design Insights

The study combined metabolic-stress models with molecular and biochemical analysis of the AMPK, SQSTM1, KEAP1, and NRF2 pathways. The experimental logic was to measure both pathway activation and the upstream events that connect nutrient status to lysosomal signaling. Readouts included SQSTM1 abundance and phosphorylation, AMPK activation, NRF2 pathway status, KEAP1 turnover, ROS-related signals, lysosomal acidification, and calcium-dependent signaling.

Mechanistic perturbations were used to test the proposed sequence rather than relying only on correlation. The authors examined the requirement for autophagic degradation of KEAP1, the participation of the AXIN–STK11–AMPK complex, and the contribution of lysosomal regulators including V-ATPase and TRPML1/MCOLN1. They also investigated phosphatase and kinase inputs, focusing on PP2A-dependent regulation of TFEB and TFE3 and TAK1/MAP3K7-dependent phosphorylation of SQSTM1.

This design is useful for researchers because it separates several often-confounded variables. Low nutrient availability was considered alongside lysosomal pH, ROS, calcium release, and extracellular proton availability. Pharmacological and genetic interventions, together with protein-interaction and phosphorylation measurements, allowed the authors to distinguish pathway dependence from a general stress response. The reported results are therefore mechanistic: they connect a change in lysosomal physiology to transcriptional control of SQSTM1 and then to reciprocal activation of AMPK and NRF2.

Protocol Parameters

• Metabolic-stress input: Use a low-nutrient or low-glucose condition as the initiating variable, while documenting the precise medium composition and exposure period for reproducibility.
• Lysosomal-state analysis: Measure lysosomal acidification and interpret it together with AMPK activity, TFEB/TFE3 status, and SQSTM1 expression rather than treating pH as an isolated endpoint.
• Pathway-dissection controls: Include interventions that test KEAP1 degradation, AXIN–STK11–AMPK complex formation, PP2A activity, TAK1 signaling, ROS, and lysosomal calcium release. These are workflow recommendations derived from the paper’s mechanistic framework, not a substitute for its condition-specific procedures.
• SQSTM1 validation: Assess both total SQSTM1 and phosphorylation at S24 and S226, because the reference study identifies these sites as important for AMPK and NRF2 activation.
• Proton control: When interpreting low-glucose experiments, distinguish intracellular lysosomal deacidification from effects caused by extracellular proton supplementation, including lactic-acid-associated conditions.

Core Findings and Why They Matter

First, metabolic stress increased SQSTM1 expression and phosphorylation. This change was linked to lysosomal deacidification produced by low glucose metabolism and AMPK-dependent proton reduction. Under these conditions, PP2A-dependent dephosphorylation of TFEB and TFE3 promoted SQSTM1 expression, providing a transcriptional route by which lysosomal stress feeds into the feedback circuit.

Second, SQSTM1 activated NRF2 by promoting macroautophagic degradation of KEAP1. Because KEAP1 normally restrains NRF2, its removal permits NRF2-dependent antioxidant transcription. This mechanism offers a direct explanation for how a protein associated with autophagic cargo handling can increase redox resilience during nutrient stress.

Third, SQSTM1 supported AMPK activation through lysosomal signaling. The study links SQSTM1 to formation of the AXIN–STK11–AMPK complex on the lysosomal membrane, a platform that enables AMPK activation during metabolic or lysosomal stress. This finding places SQSTM1 within the spatial organization of AMPK signaling rather than viewing it only as a downstream stress marker.

Fourth, SQSTM1 phosphorylation was connected to ROS- and pH-dependent lysosomal calcium secretion, which activated TAK1/MAP3K7. The functional importance of SQSTM1 phosphorylation was underscored by the finding that S24 and S226 were critical for activating both AMPK and NRF2, as detailed in the reference study.

Finally, the stress response was sensitive to proton availability. Protons supplied by lactic acid abrogated the effects associated with metabolic stress in the reported experiments. This observation is important because tumor microenvironments contain acidic metabolites and variable nutrient conditions; extracellular chemistry may therefore reshape intracellular lysosomal signaling rather than merely accompany it.

Collectively, the findings suggest that AMPK and NRF2 are not parallel emergency systems operating independently. Their coordinated activation through SQSTM1 can preserve energy management and antioxidant capacity at the same time, potentially supporting tumor growth under metabolic limitation. The model also provides a mechanistic context for studying tumors with impaired STK11 signaling and altered KEAP1–NRF2 regulation.

Comparison with Existing Internal Articles

The internal overview AMPK–SQSTM1 Feedback Loop Enhances Antioxidant Defense in Stress presents the same study as a compact explanation of reciprocal AMPK and SQSTM1 regulation. The reference paper supports a more granular interpretation: SQSTM1 connects KEAP1 degradation to NRF2 activation, organizes lysosomal AMPK signaling through AXIN and STK11, and is itself controlled through lysosomal pH, TFEB/TFE3, PP2A, ROS, calcium, and TAK1. Thus, the internal article is useful for orientation, whereas the primary study is necessary for evaluating the experimental logic and site-specific phosphorylation findings.

Limitations and Transferability

The feedback-loop model is compelling, but its transferability should be assessed experimentally. Metabolic stress is not a single condition: glucose depletion, broad nutrient withdrawal, mitochondrial dysfunction, ROS exposure, and extracellular acidification can produce overlapping but nonidentical responses. Differences in cell lineage, lysosomal capacity, basal autophagy, STK11 status, KEAP1 status, and NRF2 activity may change the relative contribution of each branch.

The findings also do not establish that every tumor with STK11 and KEAP1 alterations will use the same circuit, nor do they prove that disrupting one node will selectively eliminate cancer cells without affecting normal stress adaptation. In addition, the study focuses on intracellular metabolic and lysosomal signaling. It does not directly address neuronal TRPV1 signaling, sensory physiology, or pain phenotypes. Any extension to those systems requires an independent experimental rationale and appropriate cell-specific controls.

For follow-up work, investigators should validate pathway order with rescue experiments, compare nutrient stress with acidification-matched controls, and determine whether SQSTM1 phosphorylation changes are causal or secondary to broader lysosomal remodeling. Measurements of AMPK, NRF2, KEAP1, ROS, lysosomal pH, and calcium should be interpreted together. These precautions are particularly important when translating a tumor-cell mechanism into another biological context.

Research Support Resources

Why this cross-domain matters, maturity, and limitations

The paper’s stress-adaptation framework may provide conceptual background for researchers studying how cellular stress influences other signaling systems, but it should not be treated as evidence for a direct AMPK–SQSTM1–TRPV1 connection. For separate sensory neuron signaling studies and pain mechanism research, researchers can use AMG 9810 (SKU B7018), a selective competitive TRPV1 antagonist, to support workflows such as inhibition of capsaicin-induced calcium influx or a CGRP release inhibition assay. Its use is best interpreted as an independent TRPV1 perturbation, with solvent handling and storage guided by the product information, rather than as a reagent validated by the reference study.